【摘要】 本文观察了用羟基哌喹治疗331例矽肺病人的远期疗效。结果表明,在4～6年的临床治疗中,症状改善率在46.05～58.82％之间,X线胸片显示,有10.29％的病例好转,稳定者占66.54％,而进展者仅占14.34％。以病人自身对照治疗前后5年的胸片或配对对照法比较,均表明可使2/3病人延缓进展。生化免疫指标的测定结果也反映了病变得到控制。在长期用药中,无严重副作用发现。 远期疗效分析结果表明,羟基哌喹用于矽肺治疗时,在改善症伏,稳定病情和延缓病变进展,从而延长病人生命等方面,仍是一种较好的口服药物。更多还原

【Abstract】 331 silicosis patients have been observed for their forward therapeutic effect in continuation of the treatment with Hydroxypiperaquine. The exact therapeutic effects have shown ar follows :1.The ratio of improving the major symptoms was 46.05-58.2%.2.According to the X-ray photograph, it revealed that 10.29% of patients were improved, 66.54% were stable, and only 14.34% of the disease were in progress. The ratio of progress in cases during five years before or after treatment with Hydroxypiperaquine was 68.85% and 22.95% respectively. It means that two thirds of patientt could been retarded the progress of disease.3.The results from biochemical and immunological indexes have also shown thas the progress of the disease was controlled.None of the serious side effects was found during the continuation of treatment.更多还原